CORE Biomedicine Scores $21M Series A
2026-07-28
Tweet
BOSTON, MA, CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing.
The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. CORE's lineage-based approach is designed to identify and target core oncology drivers with precision while expanding the potential patient populations that may benefit from these novel therapies.
Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics. The company's lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, enabling the discovery of first- and best-in-class therapies with the potential to benefit broader patient populations.
Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics. The company's lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, enabling the discovery of first- and best-in-class therapies with the potential to benefit broader patient populations.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
